Loading clinical trials...
Loading clinical trials...
Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
Conditions
Interventions
SPD489 (Lisdexamfetamine dimesylate)
Matching placebo
Locations
33
United States
Sun Valley Research Center
Imperial, California, United States
Pharmacology Research Center
Los Alamitos, California, United States
Excell Research
Oceanside, California, United States
Neuropsychiatric Resesarch Center of Orange County
Santa Ana, California, United States
Connecticut Clincal Research
Cromwell, Connecticut, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Start Date
October 29, 2009
Primary Completion Date
April 18, 2011
Completion Date
April 18, 2011
Last Updated
June 8, 2021
NCT07523048
NCT07226661
NCT07115329
NCT06793397
NCT07025720
NCT06132581
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions